Pharmaceutical giant Sanofi to take over hemophilia drugmaker Biovertiv, while Celgene will buy cancer drugmaker Juno Therapeutics.

The results of two small clinical trials show that the immunotherapy is effective for multiple myeloma patients, at least in the near term.

The company has shuttered its experimental cell and gene cancer therapy unit, firing more than 100 researchers.

Juno Therapeutics asks the US Food and Drug Administration for permission to restart the CAR-T experiments without chemotherapy.

Corrections give belated credit for immunotherapy; mosquitoes have been bugging us long before Zika; the bright side of irreproducibility